Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 422

1.

Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.

Rothberg MB, Pekow PS, Lahti M, Lindenauer PK.

J Hosp Med. 2012 Jul-Aug;7(6):457-63. doi: 10.1002/jhm.1938. Epub 2012 Apr 2.

PMID:
22473716
2.

Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.

Jacobs BN, Cain-Nielsen AH, Jakubus JL, Mikhail JN, Fath JJ, Regenbogen SE, Hemmila MR.

J Trauma Acute Care Surg. 2017 Jul;83(1):151-158. doi: 10.1097/TA.0000000000001494.

PMID:
28426561
3.

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

Clin Ther. 2007 Nov;29(11):2395-405. Review.

PMID:
18158080
4.

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.

Robertson L, Strachan J.

Cochrane Database Syst Rev. 2017 Feb 14;2:CD006771. doi: 10.1002/14651858.CD006771.pub3. Review.

PMID:
28195640
5.

Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims.

Kociol RD, Hammill BG, Hernandez AF, Klaskala W, Mills RM, Curtis LH, Fonarow GC.

Clin Cardiol. 2011 Nov;34(11):682-8. doi: 10.1002/clc.20986. Epub 2011 Nov 6.

6.

Hospital-based costs associated with venous thromboembolism treatment regimens.

Merli G, Ferrufino C, Lin J, Hussein M, Battleman D.

J Thromb Haemost. 2008 Jul;6(7):1077-86. doi: 10.1111/j.1538-7836.2008.02997.x. Epub 2008 Jul 1.

7.

Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.

Costantino G, Ceriani E, Rusconi AM, Podda GM, Montano N, Duca P, Cattaneo M, Casazza G.

PLoS One. 2012;7(9):e44553. doi: 10.1371/journal.pone.0044553. Epub 2012 Sep 11. Review.

8.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.

Robertson L, Jones LE.

Cochrane Database Syst Rev. 2017 Feb 9;2:CD001100. doi: 10.1002/14651858.CD001100.pub4. Review.

PMID:
28182249
9.

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR.

J Thromb Haemost. 2013 Jan;11(1):56-70. doi: 10.1111/jth.12070. Review.

10.

Heparin-associated thrombocytopenia in 24,401 patients with venous thromboembolism: findings from the RIETE Registry.

Falvo N, Bonithon-Kopp C, Rivron Guillot K, Todoli JA, Jiménez-Gil M, Di Micco P, Monreal M; RIETE Investigators.

J Thromb Haemost. 2011 Sep;9(9):1761-8. doi: 10.1111/j.1538-7836.2011.04402.x.

11.

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA.

Cochrane Database Syst Rev. 2018 Jan 24;1:CD006649. doi: 10.1002/14651858.CD006649.pub7. Review.

PMID:
29363105
12.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group.

JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101.

PMID:
25362228
13.

Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J.

Chest. 2008 Jun;133(6 Suppl):844S-886S. doi: 10.1378/chest.08-0761.

PMID:
18574280
15.

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.

van Dongen CJ, van den Belt AG, Prins MH, Lensing AW.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001100. Review. Update in: Cochrane Database Syst Rev. 2010;(9):CD001100.

PMID:
15495007
16.

Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.

Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther KP, Weiss N, Beyer-Westendorf J.

Br J Clin Pharmacol. 2012 Dec;74(6):947-58. doi: 10.1111/j.1365-2125.2012.04302.x.

17.

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008500. doi: 10.1002/14651858.CD008500.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(8):CD008500.

18.

Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.

Kwiatt ME, Patel MS, Ross SE, Lachant MT, MacNew HG, Ochsner MG, Norwood SH, Speier L, Kozar R, Gerber JA, Rowell S, Krishnakumar S, Livingston DH, Manis G, Haan JM.

J Trauma Acute Care Surg. 2012 Sep;73(3):625-8.

PMID:
22929493
19.

Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.

Junqueira DR, Perini E, Penholati RR, Carvalho MG.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD007557. doi: 10.1002/14651858.CD007557.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Apr 21;4:CD007557.

PMID:
22972111
20.

Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.

Amin AN, Lin J, Lenhart G, Schulman KL.

Thromb Haemost. 2009 Aug;102(2):321-6. doi: 10.1160/TH09-03-0147.

PMID:
19652883

Supplemental Content

Support Center